Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 10:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Acetylcholine Clear all
Recruiting Phase 2 Interventional

Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity

NCT06617312
View directory record Official record
Conditions
Smoking Cessation, Tobacco Use Disorder
Interventions
Cytisinicline, Placebo Oral Capsule
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 20, 2026, 10:27 AM EDT
Terminated Phase 2 Interventional Results available

A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence

NCT01480232
View directory record Official record
Conditions
Nicotine Dependence, Smoking Cessation
Interventions
EVP-6124, Placebo Capsule, NicoDerm Patch (Active), NRT Patch (Placebo), Brief Supportive and Behavioral Treatment
Drug · Behavioral
Lead sponsor
A. Eden Evins
Other
Eligibility
18 Years to 65 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Sep 20, 2026, 10:27 AM EDT
Completed Phase 2 Interventional

Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior

NCT01495195
View directory record Official record
Conditions
Cocaine Use Disorders
Interventions
High-dose donepezil, Low-dose donepezil, Selegiline, Placebo
Drug
Lead sponsor
Midwest Biomedical Research
Other
Eligibility
21 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 20, 2026, 10:27 AM EDT
Completed No phase listed Observational

Cholinergic Receptor Imaging in Dystonia

NCT02689466
View directory record Official record
Conditions
Cervical Dystonia, Dystonia, Movement Disorder, Focal Dystonia
Interventions
[18F]FP-TZTP
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 20, 2026, 10:27 AM EDT
Completed Phase 3 Interventional

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

NCT01716975
View directory record Official record
Conditions
Schizophrenia, Impaired Cognition
Interventions
EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
49
States / cities
Phoenixville, Arizona • Little Rock, Arkansas • Cerritos, California + 46 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Sep 20, 2026, 10:27 AM EDT
Completed No phase listed Observational

Clinical Application of "Train of Four" Testing in the Intraoperative Monitoring Setting

NCT01932983
View directory record Official record
Conditions
Neuromuscular Blockade, Muscle Relaxation
Interventions
Train of four test
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Sep 20, 2026, 10:27 AM EDT
Completed No phase listed Observational

Improvement in Endothelial Dysfunction After Initiation of Anti-arrhythmic Therapy in Atrial Fibrillation Patients

NCT04128878
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Sotalol, Dofetilide
Drug
Lead sponsor
Samir Saba
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Sep 20, 2026, 10:27 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia

NCT03838484
View directory record Official record
Conditions
Schizophrenia, Impulsive Behavior
Interventions
Nicotine Patch, 7 Mg/24 Hr, Placebo patch
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 20, 2026, 10:27 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Nicotinic Receptor Density in Smoking and Nonsmoking Schizophrenics

NCT01246128
View directory record Official record
Conditions
Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland • Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 20, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease

NCT00766363
View directory record Official record
Conditions
Alzheimer's Disease, Central Nervous System Diseases
Interventions
EVP-6124 (0.1 mg/day), EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Comparator: Placebo, Donepezil, Rivastigmine
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
50 Years to 90 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
San Diego, California • Hallandale, Florida • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Sep 20, 2026, 10:27 AM EDT
Recruiting Phase 3 Interventional

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

NCT06607627
View directory record Official record
Conditions
Generalized Myasthenia Gravis, gMG
Interventions
Gefurulimab
Combination Product
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 20, 2026, 10:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Aricept on Biomarkers (Acetylcholine, sAPP Alpha) In Cerebrospinal Fluid

NCT00987220
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Placebo, donepezil (Aricept)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 13, 2011 · Synced Sep 20, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Varenicline (Chantix™) for the Treatment of Alcohol Dependence

NCT00705523
View directory record Official record
Conditions
Alcoholism
Interventions
varenicline, placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Sep 20, 2026, 10:27 AM EDT
Completed Phase 4 Interventional

Botox or Botox With Esophageal Dilation in Patients With Achalasia

NCT03654066
View directory record Official record
Conditions
Achalasia
Interventions
Botulinum toxin type A, Endoscope balloon dilator, Patient reported outcomes, Barium esophagram
Drug · Device · Other + 1 more
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 20, 2026, 10:27 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Endothelial Dysfunction After SCI

NCT07227727
View directory record Official record
Conditions
Spinal Cord Injuries, Endothelial Dysfunction
Interventions
Intra-arterial Infusion of Vasoactive Agents, Intra-arterial Vitamin C Infusion, Blood Sampling
Procedure
Lead sponsor
Craig Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 20, 2026, 10:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Imaging in Alzheimer's Disease

NCT00039702
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[123] 5-I-A-85380
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 20, 2026, 10:27 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Nicotine and Attention on Frequency Tuning in Auditory Cortex

NCT05018117
View directory record Official record
Conditions
Aging
Interventions
Nicotine gum, Placebo gum
Drug · Other
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 20, 2026, 10:27 AM EDT
Completed Phase 4 Interventional

Donepezil to Treat Dementia in Parkinson's Disease

NCT00030979
View directory record Official record
Conditions
Parkinson Disease
Interventions
Donepezil
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 20, 2026, 10:27 AM EDT
Terminated Phase 1 Interventional

Sildenafil to Treat HIV-Associated Pulmonary Hypertension

NCT00327080
View directory record Official record
Conditions
HIV
Interventions
MRI, L-NMMA, Acetylcholine
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 20, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Antioxidants on Skin Blood Flow-BH4

NCT03680573
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiovascular Risk Factor, Vasoconstriction
Interventions
Control: Lacated Ringers, Apocynin, Allopurinol, BH4, NG Nitro L Arginine Methyl Ester, Sodium Nitroprusside, Acetyl-ß-methylcholine chloride
Drug
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Sep 20, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Results available

Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism

NCT02552147
View directory record Official record
Conditions
Autism Spectrum Disorder, Aggression, Irritability
Interventions
Transdermal nicotine, Transdermal placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Sep 20, 2026, 10:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Relationship Between the Response to Mental Stress and Vascular Endothelial Function

NCT00975559
View directory record Official record
Conditions
Coronary Endothelial Dysfunction, Apical Ballooning Syndrome, Myocardial Infarction
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 25, 2012 · Synced Sep 20, 2026, 10:27 AM EDT
Completed Phase 3 Interventional

A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

NCT01714713
View directory record Official record
Conditions
Schizophrenia, Impaired Cognition
Interventions
EVP-6124
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
69
States / cities
Little Rock, Arkansas • Anaheim, California • Bellflower, California + 66 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Sep 20, 2026, 10:27 AM EDT
Completed Phase 2 Interventional

Niacin to Improve Blood Flow in People With Sickle Cell Disease

NCT00508989
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Niacin-ER, Placebo, L-NMMA, Acetylcholine
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Sep 20, 2026, 10:27 AM EDT